BOOK
Traditional Chinese Medicine, Western Science, And The Fight Against Allergic Disease
(2016)
Additional Information
Book Details
Abstract
This book represents a new and hopeful paradigm for treatment of diseases that are spreading globally as countries adopt Western lifestyles and standards of living. It describes the phenomenal science and clinical efficacy of the work of Dr Xiu-Min Li across a broad array of immune and inflammatory diseases. These include food allergies, asthma, eczema, 'new' diseases such as mast cell disorders, obesity, and mental health problems that are part of a worldwide 'epidemic of progress'.The most allergic people are caught in a cycle of medication, steroid dependency, emergency hospitalization, and curtailing their activities and diets to avoid triggers. Children are 'losing their childhoods.' They are fighting a battle against diet, climate change, and environmental degradation. Dr Li offers them hope by healing the entire immune system, not just address symptoms. In her practice Dr Li treats complex combinations of allergic diseases for all ages, from infancy through adulthood, bringing relief to people who have suffered terribly from oozing, bleeding skin, desperate breathing disorders, and life-threatening food allergies. She uses her vast knowledge of biochemistry to improve on the traditional decoctions to create refined versions suitable for modern tastes and lifestyles. In contrast with Western pharmaceuticals, which are the study of 'one molecule's effects on one other molecule' Dr Li's work shows the effects of multiple molecules on multiple other molecules. Increasing numbers of scientists are beginning to see the possibilities for their own research, with the prospects for more collaborations with prestigious institutions around the world. allergyblogawardsuk.co.uk/5-managing-asthma-allergies-with-henry-erlich/
Table of Contents
Section Title | Page | Action | Price |
---|---|---|---|
CONTENTS | v | ||
About the Authors | vii | ||
Acknowledgments | ix | ||
Notes on the Text | xi | ||
Foreword | xiii | ||
Introduction | xvii | ||
Chapter 1 Food Allergy | 1 | ||
Small Molecules Against IgE | 8 | ||
Predicting a Reaction | 13 | ||
“Tolerance in a Test Tube” | 15 | ||
Three Cases of Frequent Severe Food Anaphylaxis | 20 | ||
Treating Digestion | 24 | ||
Postscript | 27 | ||
Chapter 2 Asthma | 29 | ||
Changing Face of FDA Regulation | 37 | ||
First Things First — A Murine Model for Asthma Research | 39 | ||
Feasibility — Can a Herbal Treatment Work without Ephedra? | 40 | ||
Simplifying Herbal Formulas | 46 | ||
Multi-Year Research | 47 | ||
Study Design | 49 | ||
Clinical and Laboratory Evaluation | 50 | ||
Results | 50 | ||
Effects on Adrenal Function | 51 | ||
Effects on Serum IgE and Serum Cytokine Levels | 51 | ||
Safety | 52 | ||
Effect on Pulmonary Function and B2-agonist Use | 52 | ||
Effect of ASHMI Treatment on Peripheral Eosinophils | 52 | ||
Discussion | 52 | ||
Phase I Study | 54 | ||
Immunological Outcomes | 55 | ||
IFN-γ and TGF-b: Which is the Key Measure? | 58 | ||
Licorice to the Rescue? | 59 | ||
Cell Viability | 64 | ||
When Standard Medication is Not Enough | 64 | ||
Neutrophil-Dominant Asthma | 65 | ||
A Scientist’s Work is Never Done | 67 | ||
ASHMI and Mental Health | 67 | ||
“Bootleg” ASHMI | 71 | ||
Maria P — Case Study I | 72 | ||
“Donna” — Case Study II | 75 | ||
Chapter 3 Atopic Dermatitis | 77 | ||
Suffering by the Numbers | 80 | ||
Intensity | 80 | ||
The Treatment | 82 | ||
Results | 84 | ||
Medication Use | 84 | ||
Quality of Life | 85 | ||
Building a Network of Practitioners | 86 | ||
Reducing IgE to Specific Foods While Treating the Skin | 89 | ||
Dosing is a Compliance Issue | 90 | ||
“Sally G” | 90 | ||
“Megan C” | 91 | ||
Life at Age 3 | 92 | ||
Six Months Later (June 2015) | 94 | ||
Chapter 4 Inflammatory Bowel Disease | 95 | ||
Ganoderic Acid C1 (GAC1) | 99 | ||
GAC1 Inhibited TNF-α Production by RAW 264.7 Macrophages | 101 | ||
GAC1 Suppressed TNF-α Production by PBMCs from CD Subjects | 101 | ||
GAC1 Suppressed Inflammatory Cytokine Production from Mucosa from CD Subjects | 101 | ||
GAC1 Inhibited the NF-κB Signaling Pathway in PBMCs | 102 | ||
GAC1 Inhibited the NF-κB Signaling Pathway in the Mucosa | 102 | ||
One Mother’s Crohn’s Story | 102 | ||
Chapter 5 Mast Cell Activation Syndrome | 105 | ||
“Conventional Treatment” of MCAS | 108 | ||
Katherine M. — Case Study | 108 | ||
Unnamed Malady | 116 | ||
Chapter 6 Obesity | 123 | ||
Experiment 1 | 125 | ||
Experiment 2 | 126 | ||
Results | 126 | ||
Chapter 7 Future Research | 129 | ||
Project 1 | 130 | ||
Project 2 | 131 | ||
Project 3 | 132 | ||
Project 4 | 132 | ||
Project 5 | 133 | ||
Translational Research | 133 | ||
Project I | 134 | ||
Project II | 134 | ||
Project III | 135 | ||
Foods that Mimic Health Threats | 137 | ||
Collaborations | 138 | ||
Future of Practice | 139 | ||
Future of Supply | 139 | ||
Triple Therapy | 140 | ||
Appendix Information about Dr. Li’s Practice | 141 | ||
Index | 155 |